Presenters
Course Details
Poor adherence to antihypertensive medication is an important factor in the inadequate control of blood pressure worldwide. Given this impact, the 2020 ISH Global Hypertension Guidelines provided practical recommendations to help maximize antihypertensive treatment adherence. In this webinar, Professor Thomas Unger (Maastricht University, the Netherlands), the lead author of the 2020 ISH guidelines, shared these recommendations in detail. He also outlined the differences of the ISH guidelines to other international guidelines and explained the concepts of essential care and optimal care. Lastly, he discussed the crucial role of renin-angiotensin-aldosterone blockade in optimizing patient outcomes.
About the speaker
Dr. Jorge Sison is consultant in adult cardiology at the Makati Medical Center and Medical Center Manila (MCM). He is a Past President of the Philippine Heart Association, a Past Chairman of the Department of Medicine of MCM, and Past Head of the Cardiology Section of the same institution.
CPD Points: 1 Point
PRC Program No: PROG-2022-24062
Optimizing HTN Management in a Changing World: 2020 ISH Guidelines & its Clinical Applications Course Outline
- Medical Adherence
- Adherence to antihypertensive treatment is poor
- Reasons for bad Blood Pressure Control
- Reasons for Insufficient Pressure Control
- Adherence and antihypertensive therapy
- Improving Medical Adherence
- 2020 ISH Hypertension Practice Guidelines
- Introduction
- Process of Writing
- Definition of Hypertension
- Dispute: ISH- vs ACC/AHA Guidelines
- Exacerbators & Inducers of Hypertension
- Non-Pharmacological Treatment of Hypertension
- Drug Treatment of Hypertension: Thresholds and Targets
- Drug choice & Sequencing
- Drug Treatment of Hypertension Summary 1 & 2
- Ethnicity, Race and Hypertension
- Hypertension Management at a Glance
- Cardiovascular Risk Factors
- RAS in cardiovascular pathology
- Two principles of blocking the RAS
- ACE-I & ARB: Effects beyond Blood Pressure Reduction
- Who is at greatest risk of ACEI adverse events
- Adherence after one year of antihypertensive treatment
- ARBs versus ACE-I
PC-PH-103117 / August 2023